In our animal model, pretreatment with PTH also resulted in increased bone mass and a significant delay in MM progression.
However, in I-R injury model, pretreatment with NPY or (Leu, Pro) − NPY was not able to prevent cell death or rescue RGCs.
In a rat model, pretreatment with atrasentan, an endothelin-A receptor antagonist, completely prevented a TKI-induced rise in blood pressure [66].
In the reproducible ischemic flap model, pretreatment with TSA enhanced resistance to hypoxia and increased the area of surviving tissue in transplanted flaps.
In a rat remnant kidney model, pretreatment with adenoassociated viral vectors encoding angiostatin resulted in reduction in PTC density and urinary NO levels [ 156]; however, in another study, interstitial fibrosis and monocyte infiltration was ameliorated by treatment with angiostatin [ 156].
However, in the human systemic endotoxin model, pretreatment with APC does not lead to an anti-inflammatory, anticoagulant, or profibrinolytic response, although in one study the systemic mean arterial blood pressure was better preserved in the APC treatment group [ 16, 17].
For example, pretreatment with brimonidine significantly reduced axonal loss in an ischemic optic neuropathy model [ 23].
Interstitial pressure decreases by 74% in the LS174T colorectal cancer tumour model after pretreatment with A4.6.1 (Lee et al, 2000).
In this animal model, a pretreatment with PSL as the cytokine synthesis inhibitor improved the survival and attenuated the production of cytokines.
The role of RhoA/ROCK signaling was further confirmed in the nerve-crush model, where pretreatment with ROCK inhibitor Y-27632 blocked the pro-survival effect of MAG-Fc.
